

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Alteplase for the treatment of acute ischaemic stroke (review of technology appraisal 122)

Final matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (alteplase) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • AntiCoagulation Europe UK • Arrhythmia Alliance • Black Health Agency • Blood Pressure Association • Brain and Spine Foundation • British Cardiac Patients Association • Chinese National Healthy Living Centre • Counsel and Care • Diabetes UK • Different Strokes • Equalities National Council • Heart Care Partnership (UK) • Insulin Dependent Diabetes Trust • Lifeblood: The Thrombosis Charity • Muslim Council of Great Britain • Muslim Health Network • Network of Sikh Organisations • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Ambulance Service Association • Association of British Clinical Diabetologists • Association of British Neurologists • British Association for Services to the | <p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • Public Health Wales NHS Trust • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cochrane Stroke Group • CODA • Diabetes Foundation • Diabetes Research and Wellness Foundation • Juvenile Diabetes Research Foundation • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older |

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| <p>Elderly</p> <ul style="list-style-type: none"> • British Association of Stroke Physicians • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society of Neuroradiologists • Clinical Leaders of Thrombosis (CLOT) • College of Emergency Medicine • National Heart Forum (UK) • Primary Care Diabetes Society • Primary Care Neurology Society • Princess Royal Trust for Carers • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of British Neurological Surgeons • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Dorset • NHS Medway • Welsh Government | <p>People</p> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research (NIHR) Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • none |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.